Phase 2 Trial in Multiple Brain Metastases Outcomes With HA-SIB-WBRT

STATUS

Recruiting
participants needed

100
sponsor

National Cancer Centre, Singapore

Send

Updated on 19 February 2024

See if I qualify

cancer

serum pregnancy test

metastasis

treatment regimen

stereotactic radiosurgery

primary malignant neoplasm

edema

cavities

whole-brain radiotherapy

brain tumor

whole brain radiotherapy

brain metastasis

Summary

Recently, the evidence supports hippocampal avoidance with whole brain radiotherapy (HA-WBRT) as the recommended treatment option in patients with good prognosis and multiple brain metastases as it gives better neurocognitive preservation compared to historical whole brain radiotherapy controls. There is however often poor tumour control with this technique due to the low doses given. Stereotactic Radiosurgery (SRS), a form of focused radiotherapy which is given to patients who have a limited number of brain metastases, gives a higher radiation dose to the metastases resulting in better target lesion control. With improvements in radiation technology, advanced dose-painting techniques now allow a simultaneous integrate boost (SIB) dose to lesions whilst minimising doses to the hippocampus to potentially improve brain tumour control and preserve cognitive outcomes (HA-SIB-WBRT).

The Investigators believe that the SIB in HA-SIB-WBRT (experimental) will result in better functional and survival outcomes compared to HA-WBRT (control). Patients who are fit, have multiple brain metastases (5-25 lesions) and reasonable life expectancy (>6 months) will be recruited from NCCS over 2 years. Patients will be followed up the over the following year with imaging, toxicity data, quality of life, activities of daily living and cognitive measurements at set time points. The results will be compared across the 2 arms.

Patients with brain metastases are living longer. Maintaining functional independence and brain metastases control is thus increasingly important. Improved radiotherapy treatment techniques could provide better control and survival outcomes whilst maintain QoL and functional capacity.

Details

Condition	Brain Metastases
Age	21years - 80years
Treatment	HA-WBRT, HA-SIB-WBRT
Clinical Study Identifier	NCT04452084
Sponsor	National Cancer Centre, Singapore
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	-80 years old patients with radiological confirmed brain metastases (5-25 lesions)
	Histologically proven malignancy of primary cancer
	ECOG performance status 2
	Maximum lesion or cavity size 5cm
	For patients with large ( 3cm) lesions, a neurosurgical consult is recommended as the risk of cerebral oedema and hydrocephalus is higher with RT. A Ventricular-peritoneal shunt/ surgical excision may be required prior to planning of RT
	If brain surgery or other invasive procedures are performed, the treatment can only begin at least 2-weeks post-procedure
	Life expectancy of at least 6 months
	Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential
	Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control throughout protocol treatment
	Not recommended or does not want Stereotactic Radiosurgery (SRS)
	Agrees to be randomised to either HA-WBRT or HA-SIB-WBRT
Exclusion Criteria
	Prior whole brain radiotherapy
	Prior SRS is not an exclusion. Details of treatment must be recorded
	Concurrent systemic cytotoxic treatment
	If patient is on systemic treatment a treatment break of at least 7 days for immunotherapy or chemotherapy and 3 days for targeted therapy is required before and after radiotherapy
	Leptomeningeal disease
	Extensive extracranial disease, not controlled by systemic treatment
	Severe, active co-morbidity, defined as follows
	Major medical or psychiatric illness, which in the investigator's opinion would interfere with the completion of therapy and follow up or with full understanding of the risks and potential complications of the therapy
	Unstable angina and/or uncontrolled congestive heart failure
	Myocardial infarction within the last 6 months
	Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration; note that patients switched from IV antibiotics and currently on oral antibiotics whose infection is assessed to be adequately treated or controlled are eligible
	Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration
	Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive
	Dementia, ongoing psychotic episodes or moderate-severe depression (PHQ-9)
	Recent stroke in the past 3 months
	Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
	ECOG performance status >2 despite a duration of high dose steroids
	Symptomatic brain metastases limiting ADLs
	Rapid brain progression
	Patients unable to give informed consent
	Total tumour planning target volume (PTV) >60cc
	Radiological evidence of hydrocephalus
	Contraindication to Gadolinium contrast-enhanced MRI brain
	Patients who are unable to meet expected follow-up schedule (e.g. non-resident patients)
	Patients with diagnoses of small cell carcinoma, lymphoma or primary brain tumour

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

stereotactic radiosurgery

primary malignant neoplasm

edema

cavities

whole-brain radiotherapy

brain tumor

whole brain radiotherapy

brain metastasis

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Phase 2 Trial in Multiple Brain Metastases Outcomes With HA-SIB-WBRT